Merita Emini-Sadiku

Non-insulin anti diabetic agents and cardiovascular outcomes

A clinical and research approach

• Broschiertes Buch

Produktbeschreibung

Type 2 diabetes, is a major risk factor for heart failure. Treatment with non-insulin anti diabetic agents in type 2 diabetic patients with cardiovascular diseases is complex. A1C does not always reflect the real state of glucose control at diabetic patients. The latest treatment algorithms are recommended to be adapted for all type 2 diabetic patients according to ADA and the EASD in order to delay or prevent acute and chronic complications of diabetes. Metformin continues to be safe concerning the reduction of cardiovascular outcomes like MI and coronary diseases in type 2 diabetes. Several classes of diabetes medications are questionable in heart failure safety like TZDs, possibly some DPP-4-i and SUs. In our original study with type 2 diabetic patients, besides beneficial effect on insulin resistance, glimepiride fails to show improvement in diastolic dysfunction but no worsening of this function was evident. SGLT2-i and GLP-1RA besides glucose control, appear to be safe withspecific action mechanisms, in prevention of heart failure and reduction of cardiovascular death in type 2 diabetes.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 76
• Erscheinungstermin: 23. Mai 2018
• Englisch
• Abmessung: 220mm x 150mm x 6mm
• Gewicht: 132g
• ISBN-13: 9783659564512
• ISBN-10: 3659564516
• Artikelnr.: 49721042

Autorenporträt

Merita Emini-Sadiku, MD,MSc,PhD, is Internal Medicine-Endocrinology specialist and teaching assistant at University Clinical Center Kosovo. In 2012 she obtained PhD degree from School of Medicine,University of Zagreb,Croatia, where was specialized in diabetology and thyroidology. She published her research works in different international journals.